A previous clinical trial demonstrated that the anti-HER2 antibody pertuzumab, which inhibits the heterodimerization of HER2 with HER3, was beneficial when combined with trastuzumab plus docetaxel in patients with HER2-positive breast cancer [20]. This evidence concerns the gene ERBB3 and breast carcinoma.